Bacteriophage Therapy Market size is valued at USD 1,242.0 million in 2021 and is expected to reach USD 1,580.2 million by 2028, at a CAGR of 3.5% during the forecast period 2022-2028. Phages, also called bacteriophages are viruses that attack and target bacteria exclusively. They're one of the most frequent biological entities capable of fighting and killing multi-drug resistance bacteria. When all other antibiotics have failed to treat an illness, phages are able to eliminate the bacteria that are causing the infectious disease, allowing medical practitioners to save a life. Bacteriophages are being looked at as a possible antibiotic option. Viruses are utilized in this therapy to insert their genetic material into bacteria and grow using their host machinery. This phage therapy is utilized in the body of patients to treat or prevent bacterial illnesses. Bacteriophage therapy is also important in the disciplines of molecular biology and technological research. These characteristics broaden the possibility of medication development. Significant research and development activities in the bacteriophages therapy market are supporting the industry's expansion. For example, the United States Food and Drug Administration acknowledged an Investigational New Drug application from health professionals at the University of California San Diego School of Medicine in January 2019 to perform the first U.S. clinical trial of a bacteriophage-based medication intravenous administration. The planned experiment will be carried out in partnership with AmpliPhi Biosciences Corporation, a biotechnology firm based in San Diego. As per the World Health Organization, about 550 million people (almost one out of every ten people on the planet) will become ill and 430,000 will die as a result of contaminated food in 2019, resulting in the loss of 34 million healthy life years (DALYs). Additionally, the COVID-19 pandemic is posing significant challenges to companies in the worldwide bacteriophage therapy market on multiple fronts. The source of raw materials for creating medication inventions is a serious concern because to transport facility variations. Also, owing to a rise in several patients suffering from Coronavirus and other lethal conditions, goods distributors are seeing erratic demand from retailers. Key Developments: In January 2018, Pherecydes Pharma raised US$ 10.3 Mn Series B funding led by GO CAPITAL, ACE Management, and Auriga Partners to enter the clinical trials novel bacteriophages PHOSA for the treatment ofÂ Staphylococcus aureusÂ infection and PNEUMOPHAGE for the treatment ofÂ Pseudomonas aeruginosaÂ respiratory tract infections. In March 2017, Intralytix, Inc. received GRAS recognition from FDA for ShigaShield, a non-chemical antimicrobial preparation to control waterborne/foodborne bacterial pathogen Shigella including three major disease-causing species S,Â sonnei, S.Â flexneri, and S.Â dysenteriae.Â Â Moreover, company collaborated with Ferring Pharmaceuticals in bacteriophage-based inflammatory bowel disease (IBD) drug development project
Fastest Growing Market
An increase in the incidence of antibiotic-resistant bacteria strengthens the use of bacteriophage therapy. Moreover, FDA approval for bacteriophage therapies, stringent regulations for the use of antibiotics, promising pipeline drugs under various stages of clinical trials, rise in funding from the public and private sector for bacteriophage therapy research, and a wide range of applications with bacteriophage therapeutics are propelled the bacteriophage therapy market over the forecast years. Bacteriophage therapy or phage therapy is used to treat pathogenic bacterial infections with viruses. These are more specific than bacteria and do not cause any harm to host organisms as well as beneficial bacteria such as gut flora. Bacteriophages are most abundant in the biosphere and isolated, concentrated, and applied in specific areas to eradicate the bacteria. They cause the bacterium to lyse by disrupting the bacterial metabolism. The major advantages of bacteriophages over antibiotics include being very specific, replicating at the site of infection, fewer side effects, and rapidly selecting the new phages. Bacteriophages can be administered by oral, rectal, intravenous, intrapleural injections, and local applications.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.